← feed

Is NCT03254784 results overdue?

Yes — results are overdue. Primary completion was 2017-11-04; the FDAAA-801 reporting deadline (2018-11-04) passed 2786 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

NCT IDNCT03254784 ↗
SponsorBristol-Myers Squibb (INDUSTRY)
Public issuerBRISTOL MYERS SQUIBB CO — BMY (CIK 0000014272) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-11-04 (ACTUAL)
Reporting deadline2018-11-04 (completion + 365d)
Days overdue2786
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 6615bc4ef377e71f… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03254784. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →